Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A group of lymphomas displaying molecular, morphologic, immunophenotypic, and clinical overlap between classical Hodgkin lymphoma and diffuse large B-cell lymphoma. This term particularly applies to mediastinal lymphomas with overlapping features of mediastinal (thymic) large B-cell lymphoma and classical Hodgkin lymphoma.
Biomarker and diagnostic research for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma has been reported in the published literature.
No clinical trials have been registered for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma.
23 publications have been identified in PubMed for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma. Research spans Review / Meta-Analysis (39%), Case Report / Case Series (26%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 9 |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 6:40 AM UTC
Genetic and Rare Diseases Info Center
39%
Patient case studies | 6 | 26% |
Testing and diagnosis research | 3 | 13% |
Disease patterns and progression | 2 | 9% |
Other research | 1 | 4% |
Clinical study results | 1 | 4% |
Laboratory research | 1 | 4% |
Gretser S (2026). [PMID: 42008185](https://pubmed.ncbi.nlm.nih.gov/42008185/). *Pathologie (Heidelb)*. [Diagnostic / Biomarker]
Sabattini E (2026). [PMID: 41844512](https://pubmed.ncbi.nlm.nih.gov/41844512/). *Br J Haematol*. [Review / Meta-Analysis]
Donzel M (2026). [PMID: 41760436](https://pubmed.ncbi.nlm.nih.gov/41760436/). *Ann Pathol*. [Review / Meta-Analysis]
Satomi H (2026). [PMID: 41391855](https://pubmed.ncbi.nlm.nih.gov/41391855/). *J Clin Exp Hematop*. [Case Report / Case Series]
Fakhruddin N (2025). [PMID: 39662782](https://pubmed.ncbi.nlm.nih.gov/39662782/). *Hum Pathol*. [Review / Meta-Analysis]
LeHanka AM (2025). [PMID: 40119760](https://pubmed.ncbi.nlm.nih.gov/40119760/). *Pediatr Blood Cancer*. [Epidemiology / Natural History]
Zorlu T (2025). [PMID: 41562672](https://pubmed.ncbi.nlm.nih.gov/41562672/). *Hematol Rep*. [Review / Meta-Analysis]
Dudzik M (2025). [PMID: 41438804](https://pubmed.ncbi.nlm.nih.gov/41438804/). *Contemp Oncol (Pozn)*. [Case Report / Case Series]
Altay AY (2025). [PMID: 39478359](https://pubmed.ncbi.nlm.nih.gov/39478359/). *Turk J Haematol*. [Diagnostic / Biomarker]
Karube K (2025). [PMID: 38805112](https://pubmed.ncbi.nlm.nih.gov/38805112/). *Int J Hematol*. [Review / Meta-Analysis]